This Phase 2, open-label, multi-site study will explore the safety and feasibility of MDMA-assisted psychotherapy and adjunctive caregiver involvement in the treatment of 18 participants with eating disorders.
The study will enroll 12 participants with anorexia nervosa restricting-type (AN-R) and six participants with binge eating disorder (BED). A supportive caregiver, such as a parent or partner, for each participant will also be recruited to participate in the study and receive non-drug psychotherapy support. The study will consist of Preparatory Sessions, Experimental Sessions of MDMA-assisted psychotherapy, as well as Individual and Dyadic Integrative Sessions.
A flexible dose of MDMA will be given during Experimental Sessions, ranging from 80 to 120 mg with a supplemental half-dose of 40 or 60 mg 1.5 to 2 hours later, respectively, unless contraindicated. The primary outcome measure is the change in Eating Disorder Examination (EDE) results from Baseline to Visit 16 (Study Termination).
Trial Details
Trial Number
Sponsors & Collaborators
MAPSMAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.
Measures Used
Eating Disorder Examination InterviewThe Eating Disorder Examination Interview (EDE) is a semi-structured interview conducted by a clinician that has been modified to reflect the current DSM-5 diagnosis. The EDE is rated using four subscales; restraint, eating concern, shape concern and weight concern.